Product Name: Bcl10 Antibody [BL10/411]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC, WB
Applications: Flow Cytometry: 0.5-1 ug/million cellsIF: 1-2 ug/mlWB: 0.5-1 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Bcl10 antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Human Bcl10 recombinant protein (epitope localized to amino acids 122-168) was used as the immunogen for this antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 4008-48-4
Product: Nitroxoline
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Bcl-10 Antibody: CLAP, mE10, CIPER, c-E10, CARMEN, CLAP, CARD-containing molecule enhancing NF-kappa-B, Bcl-10
Accession NO.:
Protein Ino:
Official Symbol: BCL10
Geneid: 8915
Background: Bcl10, with an N-terminal caspase recruitment domain (CARD), is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t(1;14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of Bcl10 was shown to induce NFkB activation in a NIK-dependent pathway. This antibody labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t(1;14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.
PubMed ID:http://aac.asm.org/content/53/12/5015.abstract
